The cytokines IL-1, IL-6, IL-13 and IL-22 have been demonstrated to alter intestinal transcription of CLDN2 [27,28,29,30], although the impact this has on subsequent pore pathway permeability has not been fully elucidated
Always prompt and polite regarding any questions or requests Thank you
But when it comes to weight changes, its a bit different
Intriguingly, emerging evidence suggests that some newer agents such as ocrelizumab (a B cell-depleting monoclonal antibody) and siponimod (a sphingosine 1-phosphate receptor modulator with anti-inflammatory and neuroprotective properties) are beneficial in progressive MS, potentially with effects independent of suppressing acute inflammation (Montalban et al., 2017
How it works (mechanism of action) Not fully understood, but is seems to act like a cellular repair crew